GALC Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GALC Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GALC</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Galactocerebrosidase</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q31.3 (Chr14: 87,934,475-88,013,430)</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2581</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>245000</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000135837</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P54803</td>
</tr>
<tr>
<td class="label">Age of Onset</td>
<td>Form</td>
</tr>
<tr>
<td class="label">0-6 months</td>
<td>Infantile</td>
</tr>
<tr>
<td class="label">6 months - 5 years</td>
<td>Late infantile</td>
</tr>
<tr>
<td class="label">5-10 years</td>
<td>Juvenile</td>
</tr>
<tr>
<td class="label">>10 years</td>
<td>Adult</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">32 edges</a></td>
</tr>
</table>
Galc Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Function
GALC encodes galactocerebrosidase, a lysosomal hydrolase that catalyzes the hydrolysis of galactocerebroside, a major lipid component of myelin. This enzyme is essential for normal myelin maintenance and repair.
Catalytic Function
- Enzyme classification: Hydrolase (EC 3.2.1.46)
- Substrate: Galactocerebroside, psychosine
- Location: Lysosomes
- pH optimum: 4.5-5.0
Expression
- Highest expression in oligodendrocytes and Schwann cells
- Expressed in brain white matter, peripheral nerves
- Required for proper myelination
Disease Associations
Krabbe Disease (Globoid Cell Leukodystrophy)
- Autosomal recessive lysosomal storage disease
- Caused by pathogenic variants in GALC gene
- Characterized by progressive demyelination
- Infantile form: rapid neurodegeneration, death by age 2
Krabbe Disease Phenotypes
Pathogenesis
- GALC deficiency → accumulation of psychosine (toxic)
- Psychosine causes oligodendrocyte death
- Globoid cells (multinucleated macrophages) in white matter
- Severe demyelination throughout CNS and PNS
Other Associations
- Carrier status may modify risk for other demyelinating diseases
- Potential role in other leukodystrophies
Therapeutic Targeting
Hematopoietic Stem Cell Transplantation
- Early HSCT can slow disease progression
- Donor-derived [microglia](/entities/microglia) provide functional GALC
- Best outcomes when performed before symptom onset
Enzyme Replacement Therapy
- Investigational recombinant GALC (atidarsagene autotemcel)
- Challenges: [Blood-brain barrier](/entities/blood-brain-barrier) delivery
Gene Therapy
- AAV-mediated GALC delivery in clinical trials
- Early intervention critical for efficacy
Substrate Reduction Therapy
- Small molecules reducing psychosine synthesis
- Under investigation
Newborn Screening
- Implemented in many US states
- Early detection enables pre-symptomatic treatment
Key Publications
PMID:8336136 - Cloning of GALC cDNA
PMID:7566300 - Structure of GALC gene
PMID:20301638 - Long-term outcomes of HSCT
PMID:26537562 - Gene therapy trials
PMID:35215269 - Newborn screening effectivenessBackground
The study of Galc Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Krabbe Disease](/diseases/krabbe-disease)
- [Metachromatic Leukodystrophy](/diseases/metachromatic-leukodystrophy)
- ARSA Gene - Related leukodystrophy
- [Myelin](/mechanisms/myelin-integrity)
- [Oligodendrocytes](/cell-types/oligodendrocytes)
External Links
- [NCBI Gene: GALC](https://www.ncbi.nlm.nih.gov/gene/2581)
- [UniProt: P54803](https://www.uniprot.org/uniprot/P54803)
- [OMIM: 245000](https://www.omim.org/entry/245000)
- [Hunter's Hope Foundation](https://www.huntershope.org/)
VMAT2 in Disease
Parkinson's Disease
VMAT2 is a critical therapeutic target in Parkinson's disease. The vesicular monoamine transporter packages dopamine into synaptic vesicles, protecting it from oxidative degradation in the cytoplasm. Reduced VMAT2 expression may contribute to increased cytosolic dopamine oxidation and oxidative stress in dopaminergic neurons. Additionally, VMAT2 imaging can serve as a biomarker for dopaminergic neuron integrity.
VMAT2 Imaging
PET imaging with VMAT2 ligands such as [^11C]tetrabenazine and [^18F]fluoroethyl-L-tyrosine (FET) can visualize VMAT2 density in the brain. These imaging agents are used to assess dopaminergic neuron loss in Parkinson's disease and related disorders. Reduced VMAT2 binding correlates with disease severity and progression.
Pharmacological Targeting
Tetrabenazine
Tetrabenazine is a VMAT2 inhibitor approved for the treatment of chorea in Huntington's disease. By depleting vesicular dopamine, tetrabenazine reduces hyperkinetic movements. Deutetrabenazine, a deuterium analog, offers improved pharmacokinetics and reduced side effects compared to tetrabenazine.
Reserpine
Reserpine is an older VMAT2 inhibitor that depletes monoamines including dopamine, norepinephrine, and serotonin. While effective for movement disorders, its use has declined due to side effects including depression and hypotension. Research into VMAT2 modulators continues for potential neuroprotective strategies.
VMAT2 and Neuroprotection
Autophagy Regulation
VMAT2 deficiency may lead to impaired autophagy and increased susceptibility to neurodegeneration. Studies in VMAT2 knockout mice show accumulation of autophagic vacuoles and progressive neurodegeneration. This suggests that VMAT2 function is important for cellular clearance mechanisms that protect against protein aggregation.
Mitochondrial Function
Dopamine packaged in vesicles by VMAT2 is protected from mitochondrial oxidation. When VMAT2 function is impaired, increased cytosolic dopamine leads to enhanced mitochondrial reactive oxygen species production. This mechanism may contribute to the selective vulnerability of dopaminergic neurons in Parkinson's disease.
Gene Regulation
Transcriptional Control
VMAT2 expression is regulated by multiple transcription factors including Nurr1, Pitx3, and REST. These factors are important for dopaminergic neuron development and maintenance. Dysregulation of VMAT2 transcription may contribute to dopaminergic dysfunction in disease states.
Epigenetic Modifications
DNA methylation and histone modifications can affect VMAT2 expression. Studies have found altered VMAT2 promoter methylation in Parkinson's disease brains, suggesting epigenetic mechanisms may contribute to reduced VMAT2 in disease.
References
[@ref]: Ta
Pathway Diagram
The following diagram shows the key molecular relationships involving GALC Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)